A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer

Anti-Cancer Drugs

Volumn 21, Issue 10, 2010, Pages 927-931

  Dahmani, Ahmed ^a   Plater, Ludmilla De ^a   Guyader, Charlotte ^a   Fontaine, Jean Jacques ^c   Berniard, Aurélie ^a   Assayag, Franck ^a   Beuzeboc, Philippe ^b   Marangoni, Elisabetta ^a   Némati, Fariba ^a   Poupon, Marie France ^a   Pasik, Christophe ^d   Oudard, Stéphane ^a   Decaudin, Didier ^a,b  

^a Laboratory of Preclinical Investigation ^*  (France)

^b INSTITUT CURIE   (France)

^c ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^d Keocyt   (France)

Author keywords

Docetaxel; Estramustine; Prostate cancer; Resistance; Xenografts

Indexed keywords

DOCETAXEL; ESTRAMUSTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; IN VIVO STUDY; LUNG METASTASIS; MALE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; VASCULAR DISEASES; VENOUS THROMBOSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650056302     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833db887     Document Type: Article

References (20)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
2. Petrylak DP. Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit. Curr Oncol Rep 2005; 7:205-206.
3. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23:3343-3351.
4. Eymard JC, Priou F, Zannetti A, Ravaud A, Lepillé D, Kerbrat P, et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007; 18:1064-1070.
5. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, et al. Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007; 8:991-1000.
6. Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Segati R, et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 2008; 102:1080-1085.
7. Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26:5261-5268.
8. De Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancers trials 30761 and 30762. J Urol 1986; 135:303-307.
9. Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, et al. Docetaxel reintroduction in patients with metastatic hormone-refractory, docetaxel-sensitive, prostate cancer: a retrospective multicenter study. BJU International 2010; [Epub ahead of print].
10. De Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Gonçalves R, Dutrillaux AM, et al. Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol 2001; 159:753-764.
11. Oudard S, Legrier ME, Boyé K, Bras-Gonç alves R, De Pinieux G, De Cremoux P, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169:1729-1734.
12. Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boyé K, et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007; 96:269-276.
13. Né mati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 2010; 16:2352-2362.
14. Roth BJ. Combination chemotherapy in advanced prostate cancer: a silk purse. J Clin Oncol 1994; 12:2001-2002.
15. Yagoda A, Smith JA, Soloway MS, et al. Phase II study of estramustine phosphate in advanced hormone refractory prostatic cancer with increasing prostate specific antigen levels. J Urol 1991; 145:384a.
16. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer group. J Urol 1997; 157:929-934.
17. Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 2010; 22:263-267.
18. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13:1810-1815.
19. Froehner M, Hakenberg OW, Wirth MP. Molecular therapy in urologic oncology. Urol Int 2007; 79:1-7.
20. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009; 101:6-8.